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Endovascular Treatment for
Superior Vena Cava Occlusion or
Obstruction in a Pediatric and Young Adult Population
A 22-Year Experience
Aphrodite Tzifa, MD, MRCPCH,*† Audrey C. Marshall, MD,* Doff B. McElhinney, MD,*
James E. Lock, MD, FACC,* Robert L. Geggel, MD, FACC*
Boston, Massachusetts; and London, United Kingdom
Objectives The purpose of this research was to investigate the causes and symptoms of superior vena cava (SVC) obstruc-
tion or occlusion and report on the long-term results of transcatheter therapy.
Background Information on transcatheter therapy for SVC obstruction is limited.
Methods Superior vena cava catheterization interventions between August 1984 and April 2006 were reviewed. Patients
were divided into 2 subgroups depending on whether or not they had previously undergone congenital cardiac
surgery.
Results Sixty-three patients with median age of 3.7 years (range 1 month to 42 years) and weight of 13.3 kg (range 3 to
114 kg) were treated. Fifty patients (79%) were symptomatic, although only 50% had symptoms suggestive of
SVC obstruction. Superior vena cava syndrome was more common in the non-cardiac surgical group (52% vs.
10%, p  0.001). The mean gradient and SVC diameter improved from 10.8  5.8 mm Hg to 2.6  2.2 mm Hg
(p  0.001) and 3.1  2.7 mm to 9.1  3.8 mm, respectively (p  0.001). The obstruction was adequately re-
lieved in all 36 patients receiving stents and in 21 of 27 patients (78%) who had balloon dilation alone. Compli-
cations occurred in 12 patients (19%), all of whom had previously undergone cardiac surgery; 10 of these pa-
tients were successfully treated in the catheterization laboratory. Freedom from re-intervention did not differ
between patients undergoing balloon dilation or stent implantation, but was longer in patients age 5 years at
the time of intervention.
Conclusions Superior vena cava-related symptoms occur in only 50% of patients with hemodynamically significant SVC obstruc-
tion. Endovascular therapy is successful in relieving the stenosis and associated symptoms with good long-term
results. (J Am Coll Cardiol 2007;49:1003–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.060o
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ahe prevalence of superior vena cava (SVC) obstruction in
ediatric and young adult patients is largely unknown.
ausal factors have only been identified in small series or
ase reports (1–5). Long segment SVC obstruction has been
elated to surgical injury, thrombosis, infection, chronic
ndwelling catheters or devices, and external compression.
ecently, the potential for transcatheter recanalization of
bstructed or occluded venous structures has revived aware-
ess of, and interest in, SVC obstruction at our institution.
oncurrently, pediatric practices such as wider application
rom the *Department of Cardiology, Children’s Hospital and Department of
ediatrics, Harvard Medical School, Boston, Massachusetts; and the †Department of
ongenital Heart Disease, Evelina Children’s Hospital, Guy’s & St. Thomas’ NHS
rust, London, United Kingdom.o
Manuscript received August 3, 2006; revised manuscript received September 29,
006, accepted October 23, 2006.f extracorporeal membrane oxygenation (ECMO), more
requent use of central venous catheters in small patients,
ncreased implantation of transvenous pacemakers and de-
brillators (6), and a resurgence of the Mustard and Senning
rocedures (in the context of double-switch operations) may
e increasing the numbers of patients at risk for SVC
bstruction. The frequency with which SVC obstruction is
ow diagnosed at this institution has allowed us to investi-
ate, for the first time, the causes and clinical sequelae of
uch obstruction, and the results of transcatheter therapy.
e reviewed our entire 22-year experience of transcatheter
nterventions for obstructed SVC segments to try to deter-
ine and describe: 1) the most frequent underlying causes
f SVC obstruction; 2) the clinical signs and symptoms
ssociated with it; and 3) the short- and longer-term results
f transcatheter therapy.
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Patients. Medical records, car-
diac catheterization data, and an-
giograms were reviewed for all
patients with biventricular hearts
who underwent transcatheter
treatment of SVC obstruction at
oston Children’s Hospital between August 1984 and April
006, in accordance with a protocol approved by the
hildren’s Hospital Committee on Clinical Investigation.
atients with palliated univentricular congenital heart dis-
ase and SVC obstruction in the setting of a cavopulmonary
nastomosis or Fontan connection were excluded.
atheterization and SVC intervention. The technique of
alloon angioplasty and stenting of venous channels has
een described previously (7,8). Femoral venous access was
sed in the majority of patients. After angiography and
emodynamic measurements, the diameters of the SVC at
ts narrowest point and above the stenosis were recorded,
long with the length of the obstruction.
In patients with complete SVC occlusion, a jugular or
ubclavian venous line was often placed to guide SVC
ecanalization using the stiff end of a wire or a transseptal
eedle. In other cases, angiography through peripheral
ntravenous catheters in the upper extremities localized the
ourse of the veins upstream from a total occlusion.
Although technical details varied, the general interven-
ional approach is summarized below. The SVC obstruction
as initially crossed and dilated with a balloon measuring
pproximately 250% to 300% of the stenotic diameter, but
ot exceeding the diameter of the adjacent unobstructed
VC. If a waist formed on the balloon at low pressure (1 to
atm), further inflation was carried out until the waist
esolved or until the rated burst pressure of the balloon was
eached. Full inflation of the balloon with no apparent waist
as interpreted as vessel wall stretching without induction
f a therapeutic medial tear (7). In such situations, a larger
alloon was then used. When the stenosis was severe (total
cclusion or diameter 2 mm), initial dilating balloons
ere typically 4 mm. In some instances, an externalized
eno-venous wire rail (femoral-internal jugular or femoral-
ubclavian) was created to provide stability during stenting.
almaz long or XL stents (Johnson & Johnson, Piscataway,
ew Jersey) were used until June 2002, when they were
eplaced by Palmaz Genesis (Cordis, Johnson & Johnson)
r pre-mounted stents (Genesis pre-mounted, Cordis,
ohnson & Johnson). Before 2002 and in larger patients
ince 2002, stents were hand-crimped onto the appropriate
ize balloon and usually introduced via a long sheath. Relief
f obstruction was considered successful if the vessel diam-
ter increased by at least 50%, or the gradient across the
esion decreased by at least 50%.
nticoagulation. All patients who underwent SVC dila-
ion with stenting were treated with intravenous heparin
Abbreviations
and Acronyms
ECMO  extracorporeal
membrane oxygenation
SVC  superior vena cavantil therapy with aspirin (with or without clopidogrel) ead been initiated. Short- and long-term antiplatelet/anti-
oagulant therapy for patients after simple balloon dilation
ithout stenting was decided on an individual basis.
ata analysis. Outcomes assessed included acute and
hronic relief of SVC obstruction and related symptoms,
urvival, freedom from SVC re-intervention, and adverse
vents. Independent variables analyzed for association with
utcomes included age, year of surgery, balloon dilation
ersus stenting, prior cardiac surgery, complete SVC occlu-
ion, type/category of SVC obstruction, and presence and
ype of symptoms. For acute outcomes, variables of interest
ncluded acute efficacy and adverse events. Time-dependent
utcomes (survival, freedom from re-intervention) were
ssessed with the Kaplan-Meier product limit method.
actors associated with time-dependent outcomes were
nalyzed using Cox proportional hazards regression. Factors
ignificant by univariable Cox regression analysis were
ntered into a multivariable model using forward stepwise
ntry. For comparison of continuous variables between
roups, independent samples t test or the Wilcoxon rank
um test were used, and for comparison of categorical
ariables Fisher exact test or chi-square analysis was per-
ormed. Values are expressed as mean  SD or median
range).
esults
atients. Sixty-three patients underwent transcatheter
reatment for SVC obstruction. The median age at inter-
ention was 3.7 years (1 month to 42 years), and the median
eight was 13.3 kg (range 3 to 114 kg). Twenty-two (35%)
atients were infants, 23 (36%) were 1 to 17 years of age,
nd 18 (29%) were 18 years of age.
Underlying causes/types of SVC obstruction are summa-
ized in Table 1. Despite the extremely varied causes seen,
he patients were divided into 2 general groups for purposes
f data analysis and discussion: 1) postcardiac surgical group
n  41; Mustard/Senning procedures, partial anomalous
ulmonary venous return repair, cardiac transplantation,
rterial switch operation); and 2) noncardiac surgical group
n  22; postchronic line instrumentation or ECMO and 1
atient with extrinsic compression by a neurofibroma).
atients in the cardiac surgical group were older than those
n the non-cardiac surgical group (median 8.1 years, range 1
onth to 42 years vs. median 10 months, range 1 month to
9 years, p  0.001).
Although some type of presenting symptom was recorded
t the time of catheterization in 79% of patients (50 of 63),
nly one-half of patients (n  32) had symptoms suggestive
f SVC obstruction (Table 2). Of particular interest are 4
atients who presented with frequent chest infections. An
dditional 7 patients presented with primarily respiratory
ymptoms in the absence of pleural effusions. Patients in the
on-cardiac surgical group were more likely to present with
ypical SVC syndrome (52% vs. 10%, p  0.001) as
videnced by swelling affecting the upper body, upper
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March 6, 2007:1003–9 Endovascular Therapy for SVC Obstructionxtremities, neck, and face. Almost all ECMO patients (11
f 12, 92%) were symptomatic, predominantly with SVC-
elated symptoms (SVC syndrome [n  5] and pleural
ffusions [n  4]), while 2 patients presented with pulmo-
ary hypertension.
Thirteen asymptomatic patients underwent SVC inter-
ention for placement of transvenous pacing leads (n 2) or
or improvement of hemodynamically significant obstruc-
ion diagnosed incidentally at the time of catheterization
n  4) or follow-up echocardiography (n  7).
atheterization and interventions. Sixty patients with
uccessful transcatheter procedures had markedly elevated
aseline SVC pressures, with a mean gradient of 10.8 mm
g from the SVC to the right atrium. Three patients had
ailed endovascular interventions and required subsequent
urgery, due to catheter-related complications in 2 (SVC
Underlying Cause/Type of SVC Obstruction
Table 1 Underlying Cause/Type of SVC Obs
Cause/Type of SVC Obstruction
After prior atrial switch operation
Mustard
Senning
After ECMO
Congenital diaphragmatic hernia
Other pulmonary indications
Cardiac indication
After prior PAPVR repair
Warden procedure (9)
History of chronic central venous catheters
Chronic parenteral nutrition
Chemotherapy
Prolonged post-operative convalescence
After orthotopic cardiac transplantation
Operative trauma during arterial switch operation
Extrinsic compression by neurofibroma
ECMO  extracorporeal membrane oxygenation; PAPVR  partial ano
ymptoms and Indications for SVC Intervention
Table 2 Symptoms and Indications for SVC Intervention
Indication for Intervention in Symptomatic Patients
Patients
n  50
SVC-related symptoms n  32
SVC syndrome 12
SVC syndrome with frequent chest infections 2
Pleural effusions or chylothorax 12
Protein losing enteropathy with ascites 2
Hydrocephalus 2
Frequent chest infections and desaturation 2
Pacing-related recanalization in symptomatic patients n  9
Cardiac arrhythmias or syncope 9
Other symptoms leading to catheterization n  9
Limited exercise tolerance and shortness of breath 5*
Chest pain 2
Desaturation due to pulmonary vein obstruction 2f
Three of these 5 patients had pulmonary hypertension.
SVC  superior vena cava.ear with hemothorax or stent embolization) and failure to
mprove the hemodynamic condition in 1 unstable postop-
rative Senning patient.
The SVC was completely occluded and required recana-
ization in 19 of 63 patients (30%) (Fig. 1). Total SVC
cclusion was more common in the nonsurgical group (50%
s. 20%, p 0.03). Of 12 ECMO patients, 75% were found
o have total SVC occlusion. After recanalization of totally
ccluded vessels, 16 patients (84%) had stent placement,
nd in all but 3 patients, the recanalized segment was pre-
ilated before stenting.
Twenty-seven patients underwent balloon dilation alone.
he maximum balloon-to-vessel diameter ratio was 3.8 
.1, and the largest effective balloon diameter (11.4  4.9
m) was similar to the SVC diameter above the narrowing
11.2  4.1 mm). A total of 49 stents were placed in 36
atients, 10 of whom were infants. In 26 patients, the SVC
as predilated before stent deployment.
cute efficacy. Acute results of intervention are summa-
ized in Table 3. Adequate relief of obstruction was ob-
erved in 21 of the 27 patients (78%) who underwent
alloon dilation alone and in all 36 patients who underwent
tent implantation. In 30 of the 32 patients with SVC-
elated symptoms, symptomatic relief was observed after the
rocedure before hospital discharge.
All 11 patients who underwent intervention for the
urpose of placement of transvenous pacing were success-
ully treated, 8 with stent implantation and 3 with balloon
ngioplasty alone. Stent implantation was feasible in 3
atients who had existing pacemaker leads traversing the
arrowed or occluded SVC segment. Two of these patients
ad a new transvenous pacing lead inserted through the
tent soon after SVC recanalization (Fig. 2), and in 1
atient, the existing pacemaker lead remained intact and
ion
Patients Median Age (Range)
24 21.7 yrs (2 months–42 yrs)
19
5
12 4.8 months (1 month–2.3 yrs)
8
3
1
10 3.2 yrs (3 months–32 yrs)
6
9 1.9 yrs (4 months–39 yrs)
4
3
2
5 3 yrs (1 month–7.6 yrs)
2
1
s pulmonary venous return; SVC  superior vena cava.tructunctioned normally.
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Endovascular Therapy for SVC Obstruction March 6, 2007:1003–9dverse events. Complications (SVC tear, n  6; posterior
ight atrial perforation, n  2; and stent malposition or
mbolization, n  4) occurred in 12 patients (12 of 63, 19%),
0 of whom were managed in the cardiac catheterization
aboratory. All 12 of the acute complications occurred in
atients who had undergone prior cardiac surgery including 8
f 24 patients who had previously undergone a Mustard or
enning operation. One patient with an unconfined SVC tear
nd hemothorax and a second patient with an embolized stent
equired surgery. Patients who underwent balloon dilation
lone had higher incidence of SVC tears or posterior right
trial perforation (n  6) than patients undergoing stent
mplantation (n  2). Adverse events in patients who under-
ent recanalization for complete SVC occlusion included SVC
ears (n 2) and stent displacement during implantation (n
). Episodes of pulmonary or systemic thromboembolism were
ot encountered.
ollow-up. SURVIVAL. Follow-up information was avail-
ble in 62 patients (99%) at a median of 2 years (1 week to
7 years). There were 12 deaths, all from causes unrelated to
Figure 1 Complete SVC Occlusion in a 29-Year-Old Patient Wit
Operation Who Presented With Nonsustained Ventricu
The superior vena cava (SVC) was found to be occluded (left, arrow) on magne
The patient developed hemothorax during the procedure, which was managed w
nary artery.
Hemodynamic Data at Initial and Follow-Up SVC
Table 3 Hemodynamic Data at Initial and Fo
Pre
Initial SVC intervention (n  63)
SVC-to-RA mean gradient (mm Hg)
High SVC mean pressure (mm Hg)
Narrowest SVC diameter (mm)
Catheter-based SVC reintervention (n  16)
SVC-to-RA mean gradient (mm Hg)
High SVC mean pressure (mm Hg)
Narrowest SVC diameter (mm)RA  right atrium; SVC  superior vena cava.atheterization, at a median of 1.5 months after SVC
ntervention (1 day to 2 years). Factors associated with
orse survival by univariable Cox regression analysis in-
luded age 5 years at the time of SVC intervention (p 
.01) and no prior history of congenital cardiac surgery
noncardiac surgical group; p 0.008), which were strongly
ssociated with one another (p  0.002). Survival among
oncardiac surgical patients was significantly worse than
mong those in the cardiac surgery group (76% at 1 month
nd 59% at 1 and 5 years vs. 98% at 1 month, 95% at 1 year,
nd 91% at 5 and 10 years, p  0.007). However, by
ultivariable Cox regression, only age 5 years (survival
0% at 1 month, 68% at 1 year, and 63% at 5 years
ompared with 96% at 1, 5, and 10 years among patients5
ears of age) remained a significant predictor of worse
urvival. Year of surgery was not associated with survival or
ith re-intervention-free survival.
VC RE-INTERVENTION. During follow-up, 18 patients
nderwent surgery (n  2) or catheterization (n  16)
stard
achycardia
sonance imaging and was recanalized with placement of a Genesis XD stent.
ainage and placement of a second covered stent (right). MPA  main pulmo-
rventions
Up SVC Interventions
ention Post-Intervention p Value
5.8 2.6 2.2 0.001
5.8 12.2 4.8 0.001
2.7 9.1 3.8 0.001
6.1 2.6 2.1 0.001
6.4 11.1 4.4 0.001
2.1 8.3 3.1 0.001h Mu
lar T
tic re
ith drInte
llow-
-Interv
10.8
18.4
3.1
9.8
17.1
3.9
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March 6, 2007:1003–9 Endovascular Therapy for SVC Obstructionesulting in a total of 27 SVC re-interventions between 1
ay and 16 years after the initial procedure. Survival free
rom re-intervention was 90% at 1 month, 79% at 1 year,
3% at 5 years, and 35% at 10 years (Fig. 3). Freedom
rom re-intervention did not differ between patients who
ad undergone stent implantation or balloon dilation
lone at the initial procedure. By univariable Cox analy-
is, patients 5 years of age at the time of intervention (p
0.001) and those in the cardiac surgical group (p 
.003) had significantly longer freedom from re-
ntervention. By multivariable Cox analysis, only age
5 years at the time of intervention was indepen-
ently associated with longer freedom from SVC re-
ntervention (p  0.001) (Fig. 4).
Figure 2 Complete Superior Vena Cava Occlusion in a 36-Year-
and Pacing Lead In Situ, Who Presented With Near Sy
The obstruction (left, arrow) was relieved after placement of 3 Palmaz stents (rig
Figure 3 Kaplan-Meier Plot Showing Survival
and Survival Free From InterventionA total of 25 transcatheter re-interventions was per-
ormed in 16 patients. Six of 27 patients (22%) who
nderwent balloon dilation at the initial intervention had
e-intervention, including stent implantation in 5. Ten of 35
tented patients (27%) underwent re-intervention, 6 of whom
ad neo-intimal proliferation within the stent (Fig. 5), and 4
f whom had balloon dilation of the existing stent to match
omatic growth. Hemodynamic and anatomic changes at
e-intervention are summarized in Table 3. Complications
t re-intervention occurred in 2 patients (stent embolization
ith surgical stent retrieval and SVC tear with no hemo-
ynamic consequences).
atient With Mustard Operation
al Episodes and Exercise Intolerance
new pacing system was inserted a few days later.
Figure 4 Kaplan-Meier Plot Showing Effect of
Patient Age on Freedom From Reintervention
Patients 5 years of age at time of intervention
had longer freedom from re-intervention (p  0.001).Old P
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Endovascular Therapy for SVC Obstruction March 6, 2007:1003–9iscussion
lthough the literature regarding transcatheter therapy for
VC obstruction is limited to small case reports, the
easibility and acute efficacy of both balloon dilation and
tent placement in this setting are generally accepted
7,8,10–16). As a result, we are now able to examine a series
f 63 patients who presented to the catheterization labora-
ory for treatment.
In this study, we reviewed our 22-year experience of
atients who underwent endovascular therapy for SVC
cclusion or obstruction. There appeared to be 2 general
roupings of causative factors. Two-thirds of our patients
ad undergone prior cardiac surgery. Superior vena cava
bstruction in these patients is credibly related to the
econstructed anatomy, the presence of surgical anastomo-
es, or even caval cannulation sites for cardiopulmonary
ypass. Of the remaining patients, 12 had been treated with
CMO. Prior reports estimate an incidence of SVC ob-
truction after ECMO to be 10%, and it has been previously
ecognized that less than 50% of these patients present with
VC syndrome (17,18). The design of this study precludes
n estimate of the incidence of SVC obstruction at our
nstitution though, based on this prior information and on
ur own findings, we believe that SVC obstruction may
ontinue to be under-diagnosed. Almost all of the patients
n our series who had previously been on ECMO were
ymptomatic at the time of presentation to the catheteriza-
ion laboratory. Because SVC obstruction was frequently
symptomatic in the overall group of patients, and some
atients presented with symptoms other than “classic” SVC
yndrome, we speculate that there is an occult incidence of
VC obstruction in the post-ECMO population.
Our experience shows, in the largest series to date, that
Figure 5 Intimal Proliferation in Stent
Intimal proliferation was identified 10 months after placement of a Palmaz stent (
occlusion as a result of extracorporeal membrane oxygenation cannulation. The obranscatheter therapy, whether with balloon dilation or dtenting, is effective for relief of SVC obstruction and
ecanalization of SVC occlusion. Among our patients, mean
VC pressure decreased from 18 to 12 mm Hg after
ntervention, and SVC anatomy was improved. Follow-up
valuations showed a survival with freedom from re-
ntervention to be 79% at 1 year. In contrast with some prior
eports (19,20), balloon dilation resulted in lasting effect in
ome patients, with a restenosis rate of 22%. The finding
hat stent implantation was associated with a restenosis rate
f 27% is consistent with the findings of other investigators
21–23).
Procedural complications occurred only in patients who
ad undergone prior cardiac surgery, mostly in patients who
ad previously undergone Mustard or Senning operation.
he reported incidence of systemic venous baffle obstruction
fter atrial switch operation ranges from 0% to 20% (24 –
6), and endovascular therapy has been reported either
n isolated case reports or in small case series (2,3,5,10,
1,14,16). In our cohort, patients with Mustard/Senning
rocedures experienced relief of SVC obstruction after
ranscatheter therapy, but were at higher risk for procedural
omplications than other patient groups. The higher com-
lication rate related to dilation of the SVC-right atrial
unction in these patients may be due to the highly variable
ompliance of this region, which can include atrial myocar-
ial wall, suture material, pericardium, and/or prosthetic
aterial.
Patients in the noncardiac surgical group had no proce-
ural complications, despite having a higher incidence of
omplete occlusion and the need for recanalization, often
ith transseptal needles, and being substantially younger
nd smaller. Complete SVC occlusion was not associated
ith higher complication risk. This apparently low proce-
nel, arrows) in a 6-month-old infant with superior vena cava (SVC)
ion was successfully balloon dilated at re-intervention (right panel).left pa
structural risk in the noncardiac surgical group, coupled with the
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March 6, 2007:1003–9 Endovascular Therapy for SVC Obstructioncute efficacy of the procedure, supports a recommendation
o pursue diagnosis and treatment of SVC obstruction in
hese patients.
onclusions
uperior vena cava occlusion or obstruction can be success-
ully relieved by balloon dilation or stent implantation in
atients with a variety of underlying conditions. Technical
uccess and efficacy in relieving associated symptoms and
acilitating transvenous pacing are high. Symptomatic relief
chieved at the time of intervention persists at long-term
ollow-up. The procedure was associated with no mortality
nd approximately 20% morbidity. Most of the complica-
ions can be dealt with in the cardiac catheterization
aboratory. Patients who have undergone prior cardiac
urgery are at higher risk for complications, while the
ncidence of SVC tears is higher in the balloon dilation
roup. Rate of re-intervention was higher in patients 5
ears of age at the time of the initial intervention (9).
eprint requests and correspondence: Dr. Robert L. Geggel,
hildren’s Hospital, Department of Cardiology, 300 Longwood
venue, Boston, Massachusetts 02115. E-mail: robert.geggel@
ardio.chboston.org.
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